



# The TIMI Trials

## TACTICS-TIMI 18

**OBJECTIVE:** To compare invasive vs. conservative strategies among patients presenting with unstable angina and non-Q-wave myocardial infarction following treatment with the glycoprotein IIb/IIIa inhibitor tirofiban.

1. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q- wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy. *Thrombolysis In Myocardial Infarction. Am J Cardiol.* 1998;82:731-6.
2. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neuman FJ, Robertson DH, DeLuca PT, DiBattiste PM, Gibson CM, Braunwald E, for the “Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy”(TACTICS) - TIMI 18 Investigators. Comparison of early invasive versus conservative strategies in patients with unstable angina and non-ST elevation myocardial infarction treated with glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med.* 2001; 344: 1879-87.
3. Weintraub WS, Culler SD, Kosinski A, Becker ER, Mahoney E, Burnette J, Spertus JA, Feeny D, Cohen DJ, Krumholtz H, Ellis SG, Demopoulos L, Robertson D, Boccuzzi SJ, Barr E, Cannon CP. Economics, health related quality of life and cost effectiveness methods for the TACTICS (Treat Angina with Aggrastat [tirofiban] and determine cost of therapy with an invasive or conservative strategy) – TIMI 18 Trial. *Am J Cardiol.* 1999;83:317-322.
4. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLuca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. *JAMA.* 2001;286:2405-12.
5. Cannon CP, Weintraub WS, Demopoulos L, DiBattiste P, Robertson D, deLuca P, McCabe CH, Antman EM, Braunwald E, for the TACTICS-TIMI 18 Investigators. TIMI risk score to predict 6-month mortality, recurrent cardiac events, and relative benefit of invasive vs. conservative strategy in patients with unstable angina: results from TACTICS-TIMI 18. *J Am Coll Cardiol* 2001; 37 (Suppl A): 335A.
6. Cannon CP, Weintraub WS, Demopoulos L, Vicari R, Bazzino O, Ali N, Robertson DH, De Lucca PT, DiBattiste P, Rifai N, Braunwald, for the TACTICS-TIMI18 Investigators. High-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Primary results of the TACTICS-TIMI 18 C-Reactive Protein substudy. *J Am Coll Cardiol.* 2001; 37 (suppl. A): 315A.
7. Gibson CM, Murphy SA, Weisberg S, Pai R, Kraimer N, Markovic R, De Feo T, Marble SJ, Robertson DH, Demopoulos LA, DiBattiste P, Cannon CP. Early initiation of tirofiban therapy before percutaneous intervention is associated with improved flow and tissue level perfusion: A TACTICS-TIMI 18 substudy. *Circulation.* 2001;104 (Suppl II):II-548.
8. Kugelmass AD, Sadanandan S, Cannon CP, DiBattiste P, Demopoulos LA, Robertson, Braunwald E. Early invasive strategy improves outcomes in acute coronary syndrome patients with prior CABG: results from TACTICS-TIMI 18. *Circulation.* 2001;104 (Suppl II):II-548.
9. Mahoney EM, Jurkowitz C, Chu H, Alexander C, Demopoulos L, DiBattiste P, DeLuca PT, Cannon CP, Robertson DH, Weintraub W. Length of stay for the treatment of acute coronary syndromes: international experience from the TACTICS-TIMI 18 trial. *Eur Heart J.* 2001;22 (Abstr suppl):223.
10. Mahoney EM, Jurkowitz C, Spertus J, Alexander C, Robertson DH, Demopoulos L, DiBattiste P, Cannon CP, Weintraub W, Chu H. Changes in Seattle angina questionnaire (SAQ) scores following treatment for acute coronary syndromes: a follow-up evaluation from the TACTICS-TIMI 18 trial. *Eur Heart J.* 2001;22 (Abstr suppl):718.

11. Murphy SA, Gibson CM, Cannon CP, Braunwald E. Balloon size in percutaneous intervention is associated with abnormal myocardial perfusion: a TACTICS-TIMI 18 angiographic substudy. *Eur Heart J*. 2001;22 (Abstr suppl):285.
12. Sabatine MS, McCabe C, Frey MJ, Robertson DH, Antman EM. Extent of coronary artery disease and likelihood of revascularization in patients with UA/NSTEMI. *Circulation*. 2001;104 (Suppl II):II-548.
13. Sadanandan S, Cannon CP, DiBattiste P, Demopoulos LA, Robertson DH, Kugelmass AD. Outcomes of patients with spontaneous versus post PCI CK-MB elevation: data from TACTICS-TIMI 18 trial. *Circulation*. 2001;104 (Suppl II):II-697.
14. Watkins SP, De Lemos JA, Tokol G, Mahoney EM, Alexopoulos C, Goldsman D, Goldsman P, Yegin A, Bunt T, Cannon CP, Hamm CW, Weintraub WS. Cost-effectiveness analysis of tirofiban use in acute coronary syndromes. *Circulation*. 2001;104 (Suppl II):II-798.
15. Gibson CM, Morrow DA, Vicari R, Wong GC, Demopoulos LA, DiBattiste P, Murphy S, Cannon CP, Braunwald E. Elevated C reactive protein (CRP) is associated with a higher risk of thrombotic occlusion and poorer flow following percutaneous coronary intervention in patients with acute coronary syndromes: A TACTICS-TIMI 18 angiographic substudy. *J Am Coll Cardiol*. 2002;39 (Suppl A):304A.
16. Murphy S, Guigliano RP, Wong G, Cannon CP, Antman E, Gibson M. Comparison of frequency and outcomes of investigator assessed recurrent MI versus clinical event committee (CEC) adjudicated recurrent MI in acute MI trials: A Timi 14 and Timi 9 substudy. *J Am Coll Cardiol*. 2002;39:279A.
17. Sabatine MS, Morrow D, DiBattiste P, Demopoulos L, McCabe C, Gibson CM, Cannon CP, Braunwald E. ST deviation and troponin provide independent prognostic and therapeutic information in UA/NSTEMI: Results from TACTICS-TIMI 18. *Circulation*. 2002;106:2000A.
18. Sabatine MS, de Lemos J, Morrow D, Cannon CP, McCabe C, Braunwald E. Heart-Type fatty acid binding protein is an independent predictor of death and major cardiac events in acute coronary syndromes. *Circulation*. 2002;106:2259.
19. Mahoney EM, Jurkowitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos L, DiBattiste P, Cannon CP, Weintraub, WS. Cost and cost-effectiveness of an early invasive versus conservative strategy for the treatment of unstable angina and non-ST elevation myocardial infarction. *JAMA*. 2002; 288:1851-58.
20. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. *J Am Coll Cardiol*. 2002;40:238-44.
21. Kleiman NS, Lakkis N, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E for the TACTICS-TIMI 18 investigators. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. *J Am Coll Cardiol* 2002;40:1044-1050.
22. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. *Circulation*. 2002;105:1760-3.
23. Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, Robertson DH, Demopoulos LA, DiBattiste P, Cannon CP, Gibson CM. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. *Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction*. *Circulation*. 2002;106:202-7.
24. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E.: Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA* 2002;288:3124-3129.
25. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E for the TACTICS-TIMI 18 Investigators. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (the TACTICS-TIMI 18 trial). *Am J Cardiol* 2002;90:1246-1249.
26. Lakkis N, Tsyboulev V, Gibson CM, Murphy SA, Weintraub WA, DiBattiste PM, Cannon CP for the TACTICS-TIMI-18 Investigators. Outcome of patients with acute coronary syndrome admitted to hospitals with or without on-site cardiac catheterization aaboratory: A TACTICS-TIMI 18 substudy. *Crit Path Cardiol* 2002;1:232-237.

27. Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Braunwald E, Gibson CM. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes. A TACTICS-TIMI 18 substudy. *J Am Coll Cardiol* 2002;40:1761-1768.
28. Brener SJ, Murphy SA, Gibson CM, DiBattiste PM, Demopoulos LA, Cannon CP. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. *Am J Cardiol*. 2002;90:631-3.
29. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. *J Am Coll Cardiol* 2003;41:1264-72.
30. Wong GC, Frisch D, Murphy SA, Sabatine MS, Pai R, James D, Kraimer N, Katsiyannis PT, Marble SJ, DiBattiste PM, Demopoulos LA, Gourlay SG, Barron HV, Cannon CP, Gibson CM. Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. *Am J Cardiol*. 2003;91:1163-7.
31. Pinto DS, Lorenz DP, Murphy SA, Marble SJ, DiBattiste PM, Demopoulos LA, Cannon CP, Gibson CM. Association of an activated clotting time  $\leq$  250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). *Am J Cardiol*. 2003;91:976-8.
32. Bhadriraju S, Defranco AC, Barber K, Murphy S, Gibson CM, DiBattiste P, Cannon CP. Major bleeding incidence after coronary artery bypass grafting in patients with unstable angina/non-st elevation myocardial infarction based on coronary artery bypass graft timing in TACTICS-TIMI-18. *J Am Coll Cardiol*. 2003;41:374A.
33. Wong GC, Murphy S, Morrow D, Giugliano R, Cannon CP, De Lemos J, Sabatine MS, Gibson CM. A simple ECG method using high-risk infarct territory is superior to ECGs using summed ST elevation for assessing risk in ST elevation myocardial infarction. *J Am Coll Cardiol*. 2003;41:402A.
34. Sadanandan S, Cannon CP, Murphy S, Chekuri K, Partin M, DiBattiste P, Morrow D, de Lemos J, McCabe C, Braunwald E, Gibson CM. Association of B-type natriuretic peptide with angiographic findings in non-ST elevation acute coronary syndromes: A TACTICS-TIMI 18 substudy. *Circulation*. 2003;108:1759.
35. Jordan M, Dotani MI, Dumaine R, Wong G, Aroesty JM, Cannon CP, McCabe C, Braunwald E, Gibson CM. Association of multivessel disease, inflammatory markers and impaired tissue level perfusion in the setting of acute coronary syndromes: A TACTICS-TIMI 18 substudy. *Circulation*. 2003;108:2157.
36. Jordan M, Cohen DE, Wong GC, Cannon CP, Braunwald E, Gibson CM. Association of Major Bleeding with Adverse Clinical Outcomes and Length of Stay: A TACTICS TIMI 18 Substudy. *J Am Coll Cardiol* 2003;42(6) 375A.
37. Pillai M, DiBattiste P, Murphy S, Morrow D, Cannon CP, Lakkis N. Impact of troponin status and coronary artery disease by angiography on outcome in acute coronary syndrome: A TACTICS TIMI-18 substudy. *J Am Coll Cardiol*. 2004;43:307A.
38. Braganza AJM, Eminowicz G, Murphy S, DiBattiste P, Flaker GC, Cannon CP. Underachievement of low-density lipoprotein cholesterol goal in patients on statins in clinical practice: Are we using low doses of statins too often? *J Am Coll Cardiol*. 2004;43:250A.
39. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: A TACTICS-TIMI 18 substudy. *Circulation* 2004;109:580-586.
40. Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: A comparison of the Thrombolysis in Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. *Circulation* 2004;109:874-880.
41. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The impact of management strategy on clinical outcome for elderly patients with non-ST elevation acute coronary syndromes. *Ann Intern Med* 2004;141:186-95.

42. Wylie JV, Murphy SA, Morrow DA, de Lemos JA, Antman EM, Cannon CP. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: Results from OPUS-TIMI 16 and TACTICS-TIMI 18. *American Heart Journal* 2004;148:173-180.
43. McCullough PA, Gibson CM, DiBattiste PM, Demopoulos LA, Murphy SA, Weintraub WS, Neumann F-J, Khanal S, Cannon CP, for the TACTICS TIMI-18 Investigators. Timing of angiography and revascularization in acute coronary syndromes: an analysis from the TACTICS-TIMI 18 trial. *J Interv Cardiol.* 2004;81-86.
44. Herrmann HC, Murphy SA, DiBattiste PM, DeLucca, PT, Demopoulos LA, Gibson CM and Cannon CP. Greater Benefit of Early Invasive Strategy for Unstable Angina and Non-ST Elevation Myocardial Infarction in United States Compared with Non-United States Patients: A TACTICS-TIMI 18 Substudy. *Critical Pathways in Cardiology*, 2004;3(2): 95-100.
45. Gibson CM, Singh KP, Murphy SA, DiBattiste P, Demopoulos L, Cannon CP and Braunwald E for the TIMI Study Group. Association Between Duration of Tirofiban Therapy Before Percutaneous Intervention and Tissue Level Perfusion: A TACTICS-TIMI 18 Substudy. *Am J Cardiol* 2004 Aug 15;94(4):492-4.
46. Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lofti A, Morrow DA, Cannon CP, Braunwald E, Lakkis N for the TACTICS TIMI-18 Investigators. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but not critical epicardial coronary disease. *J Am Coll Cardiol* 2005;45:19-24.
47. Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, Gibson CM, Cannon CP. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. *Circulation* 2005 Mar 15;111(10):1217-24.
48. Reid IR, Tonkin A, Cannon CP. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial. *Bone.* 2005;37(2):190-1.
49. Januzzi JL, Buros J, Cannon CP. Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial. *Clin Cardiol.* 2005;28(5):238-42.
50. Moghbeli N, Kirtane AJ, Ray KK, Murphy SA, Gibson CM, Braunwald E, Cannon CP. C-reactive protein and cardiovascular outcomes in smokers versus non-smokers in non-ST-elevation acute coronary syndrome (From the TACTICS [TIMI 18] Trial). *Am J Cardiol* 2005;96:635-8.
51. Januzzi JL, Buros J, Cannon CP. Peripheral arterial disease, acute coronary syndromes, and early invasive management: The TACTICS TIMI 18 Trial. *Clin Cardiol.* 2005;28(5):238-42.
52. Moghbeli N, Kirtane AJ, Ray KK, Murphy SA, Gibson CM, Braunwald E, Cannon CP. C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 Trial). *Am J Cardiol.* 2005;96(5):635-8.
53. Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CP. Combination of Quantitative ST Deviation and Troponin Elevation Provide Independent Prognostic and Therapeutic Information in Unstable Angina and Non-ST-Elevation Myocardial Infarction. *Am Heart J* 2006 151:25-31.
54. Morrow DA, Sabatine MS, Cannon CP, Murphy SA, Brennan M-L, Hazen SL, Braunwald E. Concurrent evaluation of novel cardiac biomarkers in ACS: Myeloperoxidase, sCD40L, C-reactive protein and risk of death or recurrent ischemia in TACTICS-TIMI 18. *J Am Coll Cardiol* 2006;47:196A.
55. Kugelmass AD, Sadanandan S, Lakkis N, Dibattiste PM, Robertson DH, Demopoulos LA, Gibson CM, Weintraub WS, Murphy SA, Cannon CP. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: A report from TACTICS-TIMI 18. *Crit Pathw Cardiol.* 2006;5(3):167-72.
56. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Concurrent Evaluation of Novel Cardiac Biomarkers in Acute Coronary Syndrome: Myeloperoxidase and Soluble CD40 Ligand and the Risk of Recurrent Ischemic Events in TACTICS-TIMI 18. *Eur Heart J.* 2008;29:1096-102.